Tarsa to submit NDA for Ostora in 2012
The initiative follows a formal pre-NDA verification with the FDA that verified the results from Tarsa’s Phase III ORACAL trial and the requirements for regulatory approval. The Phase
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.